(lp0
S'Form 8-K REPROS THERAPEUTICS INC. For: Apr 17 StreetInsider.com - 20 hours ago THE WOODLANDS, Texas, April 17, 2017  -- Repros Therapeutics Inc.  today announced the issuance of a new patent, U.S.Session Recap: Viewing Unusual Volume for Repros Therapeutics Inc.  - The Herald'
p1
aS'Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2016 Financial ... GlobeNewswire  - Mar 31, 2017 G&amp;A operating and occupancy expense, which includes expenses to operate as a public company, decreased 7%, or approximately $134,000, to $1.7 million for 2016 as compared to $1.8 million for 2015.Repros Therapeutics reports 4Q loss - Yahoo FinanceRepros Therapeutics Inc.  Files An 8-K Results of Operations and ... - Market Exclusive'
p2
aS'1.30 MarketWatch - Jul 23, 2009 Repros Therapeutics Inc. Watchlist CreateRPRXAlert. Premarket. Last Updated: Apr 17, 2017 9:23 a.m.. $ 1.30. 0.21 19.27%.'
p3
aS'Repros Therapeutics stock halted after FDA says partial clinical hold will ... MarketWatch - Apr 10, 2017 Repros Therapeutics Inc. RPRX, +6.43% shares were halted in premarket trade Monday on news that the Food and Drug Administration would continue a partial clinical hold for its drug for uterine fibroids, or tumors in the uterus.Repros Therapeutics  Names Larry Dillaha as CEO - StreetInsider.comRepros Names Larry Dillaha, MD, its Permanent President and CEO - GlobeNewswire '
p4
aS'Inside the Numbers on Shares of Repros Therapeutics Inc.  BVN - 8 hours ago Looking at shares of Repros Therapeutics Inc. , the company presently has a Gross Margin  ratio of 0.005367.'
p5
aS'Repros Therapeutics Inc.  KORNIT DIGITAL LTD. (NASDAQ:KRNT ... Rives Journal - 18 hours ago Repros Therapeutics Inc.  shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm.'
p6
aS'Repros Therapeutics Inc. RPRX  Wall Street Journal - Feb 12, 2011 Repros Therapeutics Inc. RPRX . search. View All companies. AT CLOSE 4:00 PM EDT 04/07/17. $1.11 USD; 0.00 0.00%.'
p7
aS'Why Repros Therapeutics, Inc. Shares Are Soaring Motley Fool - Apr 2, 2015 What: Shares in Repros Therapeutics  vaulted higher by 10% earlier today after announcing that the FDA had accepted its application for approval of its drug Androxal.'
p8
aS"Repros Therapeutics Inc.  Files An 8-K Departure of Directors or ... Market Exclusive - Apr 13, 2017 On April 9, 2017, Larry Dillaha, M.D., was named the permanent President and Chief Executive Officer of Repros Therapeutics Inc. , and was also appointed to the Company's Board of Directors . Dr. Dillaha had served as the&nbsp;..."
p9
aS'Repros Announces New CEO GlobeNewswire  - Feb 2, 2017 THE WOODLANDS, Texas, Feb. 02, 2017  -- Repros Therapeutics Inc.  today announced that Joseph S. Podolski is leaving his position as President and Chief Executive Officer and member of the Board of Directors to&nbsp;...'
p10
a.